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Aluminum transfer during hemodialysis. Aluminum concentra-
tions were measured in plasma and urine of normal subjects and
chronic hemodialysis patients by using fiameless atomic absorp-
tion spectrophotometry. Plasma aluminum averaged 7 jzglliter in
13 normal subjects, who excreted an average of 13 gIday.
Predialysis plasma concentrations in 16 patients on low aluminum
dialysate (study A) averaged 58 zgIliter, with a postdiaiysis mean
of 63 ,uglliter (P <0.02). Urinary aluminum excretion averaged 9
gIday during the longest interdialysis interval. Nineteen patients
using high aluminum dialysate (stuby B-i) had mean plasma con-
centrations of 168 predialysis and 265 gIliter postdialysis (P <
0.001). and they excreted 48 jzg/day of aluminum (P < 0.01 vs.
study A). After two months of dialysis with low aluminum dialy-
sate (study B-2), 14 patients were restudied. Predialysis aluminum
concentration averaged 93, and postdialysis, 114 gI1iter (P <
0.05). Both pre- and postdialysis plasma levels differed significant-
ly among the three groups. During study B-2, aluminum excretion
averaged 19 rg/day, significantly less than study B-i (P < 0.01).
One patient was dialyzed for 60 mm with dialysate containing 128
jzg/liter aluminum, and for the subsequent 140 mm, with 3 pg/liter
aluminum dialysate. Plasma aluminum before dialysis was 43 rg/
liter. Values across the dialyzer at 15 mm were 76 and 195 gIliter:
at 60 mm, 148 and 205 zgIiiter; and at 200 mm, 110 and 114 g/iiter.
We conclude that significant amounts of aluminum can be trans-
ferred to plasma during dialysis if dialysate contains virtually any
aluminum since aluminum is bound to a nondialyzable plasma
constituent. The binding also precludes the removal of aluminum
from the patient during dialysis.
Transfert d'aluminium an cours de l'hémodialyse. Les concen-
trations d'aluminium ont été measurées dans le plasma et l'urine
de sujets normaux et de malades soumis a l'hemodialyse iterative
par spectrophotométrie d'absorption atomique sans flamme. La
concentration plasmatique est en moyenne de 7 tg/litre chez 13
sujets normaux qui excrètent une moyenne de 13 fLgljour. La
concentration plasmatique avant la dialyse chez 16 malades pour
lesquels un dialysat pauvre en aluminium est utilisé (étude A) est
en moyenne de 58 ,ugllitre. Aprés la dialyse Ia moyenne est de 63
sgIlitre (P < 0,02). L'excrétion urinaire d'aluminium est en moy-
enne de 9 zgIjour au cours de l'intervalle le plus long entre les
dialyses. Dix neuf malades pour lesquels un dialysat nche en
aluminium est utiisé (étude B-I) ont des concentrations plasma-
tiques moyennes de 168 avant la dialyse et 265 g/lilre apres la
dialyse (P <0,001). ils excrètent 48 zg!jour (P <0,01 par rapport
a l'étude A). Quatorze malades ont été étudiés a nouveau après
deux mois de dialyse avec un dialysat pauvre en aluminium (étude
B-2). Les concentrations plasmatiques sont de 93 avant et 114 jrgl
litre après Ia dialyse (P <0,05). Les concentrations plasmatiques,
aussi bien celles d'avant que celles d'après Ia dialyse, sont signifi-
cativement différentes dans les trois groupes. Au cours de l'étude
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B-2, l'excrétion urinaire est en moyenne de 19 1.rgljour, significa-
tivement moms qu'au cours de l'étude B-i (P <0,01). Un malade
a été dialysé pendant 60 mm avec un dialysat contenant 128 jtgl
litre d'aluminium puis, pendant les 140 mm suivantes, avec un
dialysat contenant 3 pg/litre, La concentration plasmatique
d'aluminium avant la dialyse était de 43 tg/litre. Les valeurs de
part et d'autre do dialyseur étaient de 76 et 195 gIlitre a 15 mm,
148 et 205 pg/litre a 60 mm, 110 et 114 pg/litre a 200 mi Nous
concluons que des quantités non negligeables d'aluminium peu-
vent étre transférées vers le plasma au cours de Ia dialyse si le
dialysat contient si peu que ce soit d'aluminium du fait que celui-ci
est lie a one fraction plasmatique non dialysabte. Cette liaison
empéche aussi de soustraire de l'aluminium au malade au cours de
la dialyse.
Elevated concentrations of aluminum have been
reported to exist in plasma and tissue samples of
dialyzed and nondialyzed patients with chronic renal
failure [1—4]. There are two apparent environmental
sources of aluminum responsible for altering body
stores in dialyzed uremic patients. Aluminum may
enter the body via the gastrointestinal tract following
the ingestion of aluminum-containing compounds ti 1,
5—7], or via the blood during hemodialysis, There-
fore, to determine the effects of dialysate aluminum
on the patients' metabolism of aluminum, we have
studied chronic hemodialysis patients from dialysis
units with different dialysate aluminum levels.
Methods
Sixteen patients from Unit A which had a low
aluminum dialysate and 19 from Unit B with high
aluminum dialysate were studied. The study was
repeated in 14 patients from Unit B two months after
the aluminum content of the dialysate was reduced to
low levels (study B-2). Two to four pairs of pre- and
postdialysis blood samples were obtained from all
patients. Thirteen patients from Unit A and nine
patients from Unit B collected timed urine samples
during the longest interdialysis periods.
The patients from Unit A averaged 52 9 years in
age, with a range of 31 to 63 years. The eight males
and eight females had been treated with hemodialysis
for 26 19 months, with a range of 2 to 57 months,
The patients from Unit B averaged 51 11 years in
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age, with a range of 22 to 67 years, were all male, and
had undergone hemodialysis for 43 26 months,
with a range of 8 to 82 months. The average dura-
tions of dialysis of the two groups differed (P <
0.05).
All patients remained on their usual dialysis sched-
ules and medication regimens, which in all instances
included aluminum-containing phosphate binders,
The prescribed dose of phosphate binders was com-
parable in all studies. Unit A patients used coil dialy-
zers (Travenol Laboratories, Inc., Morton Grove,
IL) with a central dialysate proportioning system
supplied with water purified by reverse osmosis.
Unit B patients used hollow fiber artificial kidneys
(Cobe Laboratories, Inc., Lakewood, CO) with a
central proportioning system using water purified by
reverse osmosis. At the time of the initial study (B-i)
and for the preceding eight months, the reverse
osmosis equipment in Unit B was functioning at a
suboptimal level. This was remedied two months
before study B-2.
Blood was drawn into heparinized vacuum tubes,
centrifuged, and the plasma transferred to plastic
tubes. Urine was collected in plastic bags doubly
rinsed with deionized, aluminum-free water. Vol-
umes were measured and aliquots transferred to
plastic tubes.
One patient was studied during dialysis with a
hollow fiber artificial kidney (C-DAK Model 4, Cor-
dis Corporation, Miami, FL) and an individual
dialysate proportioning system. A baseline venous
blood sample was obtained. The patient began
dialysis using dialysate prepared with filtered tap
water for one hour, followed by dialysis for four
hours using dialysate prepared with water purified by
reverse osmosis. Blood was obtained from the arteri-
al and venous lines at 15, 60. and 200 mm. Simultane-
ous inflow and outflow dialysate samples were
obtained at 60 and 200 mm. Blood flow averaged 212
mi/mm, and dialysate flow, 500 mL/min,
Pre- and postdialysis plasma samples were also
obtained from five dialysis patients in Minnesota
where the dialysate was prepared from filtered tap
water with a high aluminum content.
Thirteen normal subjects donated two to five plas-
ma samples and four to seven daily urine collections,
which were analyzed for aluminum and creatinine.
Part of these control data has been reported else-
where [71.
Plasma, urine, water, and dialysate aluminum con-
centrations were determined by flameless atomic
absorption spectrophotometry [7, 81. Measurements
were performed using an atomic absorption spectro-
photometer (Perkin-Elmer, Model 305-B, Norwalk,
CT) equipped with an HGA-2 100 flameless system
whose control module was electronically modified to
gradually increase the temperature during the char
cycle. Absorption measurements were recorded on a
strip chart recorder. The program for the HGA-2i00
is: dry cycle, 50 sec at 100°C; char cycle, 60 sec to
1550°C, atomize cycle, 8 sec at 2760°C; argon gas
purge, 60 mI/mm constant flow. The 305-B settings
are: Al hollow-cathode lamp, 309.3 nm at 25 milli-
amperes; slit width i mm (0.7 nm bandpass); absorp-
tion mode.
in the present study, 25-pA plasma samples were
injected directly into the graphite tube via an Eppen-
dorf pipette (Brinkmann Instruments, inc.. Wes-
bury, NY), followed by injection of 5 pA of Triton X-
iOO (Harleco, Philadelphia, PA) to prevent organic
residue buildup. Twenty-five microliter urine samples
were analyzed similarly, but without addition of Tri-
ton X-lOO. Urine samples with high aluminum con-
centrations were diluted with deionized water so as
to read between 0.1 and 0.3 absorbance units. All
analyses were done in duplicate.
Since no form of pretreatment was required, con-
tamination sources were virtually eliminated. The
Triton X-l00 did not contain detectable aluminum.
Aluminum-free deionized water was handled identi-
cally to both blood and urine samples and then ana-
lyzed. This resulted in a maximum aluminum addi-
tion of 3 tg/liter for both procedures. Since there
was no noise in the system, the detection limit,
defined as twice this blank, was 6 tg/liter. Blanks
were subtracted from all plasma and urine determi-
nations. The sensitivity, defined by 44 milliabsorb-
ance units, is 1.5 pg/liter of aluminum. To further
verify the analysis, standard additions were per-
formed with plasma and urine samples from 17 sub-
jects. The recovery of added aluminum from plasma
was 99.5 4.7%; from undiluted urine, 87 4%;
and from urine diluted tenfold, 100.6 3.6%. Back-
ground correction was unnecessary. Although no
significant interferences with aluminum detection
were found with plasma, urine, or water, the alumi-
num signal was suppressed in dialysate. Therefore,
the standard additions technique described by Fuller
was used to correct the dialysate aluminum concen-
trations [9]. Creatinine concentrations were mea-
sured by an automated method [10].
Statistical comparisons of two groups were made
with Student's t test. Three groups were compared
by analysis of variance and Scheffe's test of signifi-
cance [11]. The 95% level of confidence (P < 0.05)
was regarded as significant, The exception to this
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policy was the analysis of urinary aluminum excre-
tion data. In order to take advantage of the paired B-
1 and B-2 study data, t testing was used to compare
study B-i with study A (unpaired) and study B-2
(paired). Since two t tests were performed on the
same data from study B-I, a confidence level of
97.5% (P < 0.025) was demanded for significance.
Variance is expressed throughout as 1 SD.
Results
The mean predialysis concentrations of plasma
aluminum in the three studies were significantly high-
er than the average concentration found in normal
subjects (7 2 jsglliter) (Fig. 1). In each study,
plasma aluminum concentrations rose during dialy-
sis: study A, P <0.02; study B-i, P <0.001; study
B-2, P < 0.001. Both pre- and postdialysis values
differed among the groups: A vs. B-i, P < 0.001; A
vs. B-2, P < 0.05, B-i vs. B-2, P < 0.001. The
highest postdialysis plasma aluminum seen in any
patient was 398 LgIliter. Plasma aluminum concen-
trations fell significantly between the end of dialysis
and the start of the next dialysis in studies B-i and B-
2, but not in study group A. The values obtained
from the longest interdialysis interval for each
patient are presented in Table 1. Predialysis plasma
aluminum concentrations did not correlate with the
overall duration of hemodialysis.
Table 2 displays the urinary excretion data
obtained during the three studies and from normal
350
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Table 1. Changes in plasma aluminum concentrations during the
interdialysis period
Plasma aluminum. sg/liter
Study group N Postdialysis Predialysis Change
A 14 59±26 55±28 —4± 21
B-I 18 303 76 162±66a —151 ll5
B-2 14 114 39 84 28e —30 28
subjects. The urine aluminum concentrations, excre-
tions per 24 hr, and excretions per g of creatinine
were significantly greater in study B- 1, compared to
studies A and B-2. The fractional excretions of alu-
minum do not appear different among the three
studies.
Tap water obtained from the Minnesota dialysis
unit contained 386 tg/liter aluminum. Following fil-
tration the aluminum concentration was 200 gJliter.
The pre- and postdialysis plasma aluminum concen-
trations averaged 143 37 and 272 37 sgIliter,
respectively (P < 0.01).
Values obtained during one dialysis in a single
patient are presented in Figure 2. The dialysate con-
tained 128 pg/liter of aluminum. Plasma aluminum
rose from 43 tgIliter at the start of dialysis to 148 g/
liter after 60 mm and then fell to 110 j.tg/liter after the
subsequent 140 mm of dialysis with a Low-aluminum
dialysate. The data at 60 mm indicates an aluminum
transfer from the dialysate of 20.5 sg/min.
Discussion
This study shows that aluminum is readily trans-
ferred from dialysate to plasma during hemodialysis.
Although plasma aluminum exceeds dialysate alumi-
num concentration, aluminum continues to move
from dialysate to blood. Even with very low concen-
trations of dialysate aluminum, little if any aluminum
appears to be removed from plasma by dialysis.
These findings indicate that aluminum is strongly
bound to a plasma component. Plasma binding sites,
however, appear to be saturable. This latter postu-
late is supported by the following evidence: a
reduced rate of aluminum uptake at 60 mm compared
to 15 mm of dialysis, the rarity of postdialysis alumi-
num concentrations over 300 pg/liter, and the com-
parable postdialysis concentrations seen in the Min-
nesota patients (dialysate aluminum, 200 tglliter)
and in study B-i patients (dialysate aluminum, 66 g'
liter).
a Different from predialysis values. P < 0.001.
Different from study A. P <0.001: different from study B-2. P <
0.01
Different from predialysis values. P < 0.01.
E
E
=
200
150
100
50
Study A Study B-
Fig. 1. Aluminum concentrations of the water used to prepare
dialysate (solid bars), predialysis (open bars) and posidinlysis
(hatched bars) plasma samples from the three studies. Length of
vertical lines indicates 1 SD. Statistical comparisons are discussed
in the text.
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Table 2. Urinary excretion of aluminum by chronic hemodialysis patientsa
C, clearance; Cr, creatinine; V, volume; U, wine; E, excretion; Al,
The significantly greater plasma and urinary alumi-
num concentrations in the patients from study B-I
provide evidence for the occurrence of aluminum-
loading when dialysate has a high aluminum content.
Patients using high aluminum dialysate demonstrated
an intradialysis increase in plasma aluminum of
about 100 tg/liter. If the distribution of aluminum is
confined only to plasma volume, this change could
reflect the addition of at least 300 g of aluminum
during each dialysis. Although mean daily excretion
of aluminum was increased to about 50 gIday, this
would account for only 350 g of a 900-/Lg weekly
load. Although gastrointestinal excretion, perhaps
via biliary secretion, could unload some of this bur-
den, tissue deposition appears to be a much more
likely fate for the aluminum load. Based on tissue
analyses in our laboratory, we have estimated total
body aluminum in normal individuals to be about 30
mg. Thus, chronic retention of 550 g of aluminum
per week would severely alter body aluminum
stores.
This study shows that use of dialysate containing
aluminum can increase the body aluminum burden.
Water treatment thus assumes a critical role in con-
trol of aluminum delivery to the dialyzed uremic
patient. Although water was treated by reverse
osmosis during study B-i, concentrations of alumi-
num were elevated since the rejection rate for alumi-
num was only 80%, which yielded treated water with
aluminum concentrations reaching 70 igIliter. Since
aluminum is widely used as a flocculator in public
water supplies without regulated standards for alumi-
num content of water, it is expected that water sup-
plies in many cities in this country have aluminum
levels of 300 to 500 p.g/liter. If this water is used for
dialysis, purification systems should remove at least
97% of the aluminum in order to achieve levels that
will probably not increase plasma aluminum
concentrations.
Patients maintained on a low aluminum dialysate
also have elevated concentrations of plasma alumi-
num (study A). This is most likely a result of absorp-
tion of some aluminum from the aluminum-contain-
ing phosphate-binding gels routinely administered to
these patients. The small increase in plasma alumi-
num during dialysis in study A can readily be
accounted for by plasma concentration from ultrafil-
tration. Normal individuals receiving aluminum com-
pounds in comparable dosages to dialysis patients
can absorb up to 1 mg of aluminum per day [7]. In
view of the compromised ability to excrete aluminum
because of the marked impairment of renal function
and the inability to dialyze aluminum from plasma,
the aluminum absorbed from these aluminum com-
pounds would also tend to be retained by the
Study group N
Cr
mi/ruin
V
m1124 hr
UA
pg/liter
EAI
p.g124 hr
EAI/ECr
pg/g
FEA!
%
A 13 1.23±2.13 194±264 54±21 9±9 120±67 18±12
B-I 9 1.09 0.83 229 lSOb 330 251e 48 19d 564 542C 23 24
B-2 9 0.86 0.51 182 97 117 77 19 9 229 219 19 11
Normal subjects 13 128 18 1374 492 11 5 13 5 9.1 3.1 1 0.5
Values are given as the mean SD. Abbreviations used are:
aluminum; FE, fractional excretion.
Not statistically different from A or B-2.
Different from A, P < 0.01; different from B-2, P <0.01.
d Different from A and B-2, P <0.001.
Different from A and B-2, P <0.02.
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Fig. 2. Aluminum concentrations qf plasma and dialysate during
hemodialysis of one patient. Di and Do refer to dialysate entering
or leaving the dialyzer. Filtered tap water was used to prepare the
dialysate during the initial 60 mm of study; water treated by
reverse osmosis was used thereafter.
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patients. The combination of uptake of aluminum
from the dialysate and absorption of aluminum from
the phosphate-binding gels can account for the mark-
edly increased body aluminum content found in
almost every chronically dialyzed uremic patient [4].
Evidence has been presented which suggests that
aluminum may be responsible for the dialysis-associ-
ated encephalopathy syndrome. Brain gray matter
aluminum has been found to be significantly higher in
dialyzed uremic patients who have died from this
syndrome as compared to dialyzed uremic patients
who have died from other causes [3, 12]. This link
between dialysate aluminum, brain aluminum, and
dialysis encephalopathy has been pointed out by
Flendrig, Kruis, and Das [13]. Six patients from a
dialysis unit using dialysate prepared from tap water
heavily contaminated with aluminum developed
dialysis encephalopathy. No patients from the other
dialysis unit in the same city, using identical equip-
ment but with uncontaminated tap water, developed
the syndrome. Aluminum content of brain and other
tissues was much greater in the patients with dialysis
encephalopathy than in chronic dialysis patients
without the syndrome from other dialysis units. Tak-
en together, this evidence strongly supports the
hypothesis that the dialysis encephalopathy syn-
drome is due to deposition of aluminum in the brain,
particularly the gray matter. The aluminum deposit-
ed in the gray matter most likely comes from two
sources, the aluminum contamination present in the
dialysate and the orally administered phosphate
binders. Thus, dialysis centers using dialysate with
high aluminum concentrations might be expected to
have a higher incidence of dialysis encephalopathy,
thereby explaining the variation in frequency of this
syndrome in different regions of the world.
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